FMP

FMP

Enter

PTCT - PTC Therapeutics, In...

photo-url-https://images.financialmodelingprep.com/symbol/PTCT.png

PTC Therapeutics, Inc.

PTCT

NASDAQ

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

54.5 USD

1.74 (3.19%)

PTCT Financial Statements

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Total Revenue

213.17M

196.79M

186.7M

210.12M

Cost of Revenue

16.28M

10.85M

18.39M

66.27M

Gross Profit

196.89M

185.94M

168.31M

143.85M

Operating Expenses

359.28M

240.45M

201.67M

189.4M

Research and Development

124.77M

161.41M

132.17M

116.13M

Selling, General & Administrative Expenses

84.68M

73.46M

69.5M

73.27M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

0

0

0

0

Other Expenses

149.82M

5.58M

-2.02M

1.59M

Operating Income

-162.39M

-54.51M

-33.36M

-45.55M

Total Other Income/Expenses Net

67.69M

-43.48M

-45.52M

-39.14M

Income Before Tax

-94.7M

-97.99M

-85.73M

-84.7M

Income Tax

-28.81M

8.66M

13.45M

6.88M

Net Income

-65.89M

-106.65M

-99.18M

-91.58M

Basic EPS

-0.86

-1.39

-1.29

-1.2

EPS Diluted

-0.86

-1.39

-1.29

-1.2

Basic Average Shares

76.85M

76.93M

76.73M

76.5M

Diluted Average Shares

76.85M

76.93M

76.73M

76.5M

EBITDA

-46.88M

-54.51M

-35.23M

11.53M

Retained Earning Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Retained Earnings (Previous Year)

-3.58B

-3.47B

-3.38B

-3.28B

Net Income

-65.89M

-106.65M

-99.18M

-91.58M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-3.65B

-3.58B

-3.47B

-3.38B

Other Distributions

-65.89M

-106.65M

-99.18M

-91.58M

PPE Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Gross PPE

117.66M

122.64M

123.12M

183.97M

Annual Depreciation

6.76M

6.49M

7.02M

55.4M

Capital Expenditure

-6.5M

54.24M

7.38M

-64.35M

Net PPE

117.39M

61.91M

108.73M

192.92M

Intangible and Goodwill Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

82.34M

82.34M

82.34M

82.34M

Goodwill

82.34M

82.34M

82.34M

82.34M

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep